/
Medicinal chemicals & botanical products company · NV · FY ends Dec · Revenue $24M · -9.37% margin · -$6M FCF
$0.27
+$0.00 (+0.00%)
Price from 26 days ago
The business is unprofitable at the operating level (-10.35% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 169.4% YoY with margins expanding 32.2pp.
Negative free cash flow of -$6M. The business is consuming cash, not generating it.
16.8x earnings. Valuation is in a reasonable range. The main question is whether the business can re-accelerate or if current trajectory is already priced in.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$24M
▲ +169.4% YoY
Net Income (TTM)
$5M
▲ +208.2% YoY
Op. Margin
-9.37%
▲ +32.2pp YoY
ROIC
-51.99%
▲ +47.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$6M
▼ -257.9% YoY
Op. Cash Flow (TTM)
-$6M
▼ -256.4% YoY
Net Debt
-$64K
Net Cash Position
Cash & Equiv.
$640K
5Y CAGR: +4.6%
Continue Research